P299 Serine protease PRSS11/HtrA1 dysregulates aggrecan metabolism in human articular cartilage  by unknown
Osteoar thr i t i s  and Cart i lage Vol. 13, Supp lement  A $149 
P299 
SERINE PROTEASE PRSS11/HtrA1 DYSREGULATES 
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Aim: To investigate metabolic onsequences of PRSS11 expres- 
sion in human articular cartilage. 
Methods: Transcriptional profiling and mass spectrometry-based 
proteomic analyses were performed on human osteoarthritic ar- 
ticular cartilage specimens to identify altered gene expression as- 
sociated with osteoarthritis (OA). To further investigate the role 
of one such protein product, PRSS11, human chondrocyte cul- 
tures were infected with adenoviral constructs encoding active 
PRSS11 protease ora PRSS11 active site mutant (ASM; $328A). 
Human chondrocyte cultures were also exposed to PRSS11 ag- 
onist peptide CPII/III, which comprises the C-terminal 6-amino 
acid sequence present on the C-propeptides of collagens II 
and III, and which binds to the PDZ domain of PRSS11 with 
high affinity. Proteoglycan (aggrecan) content was monitored by 
DMMB assay. Quantification of mRNAs for aggrecan, ADAMTS- 
4 (aggrecanase-1) and ADAMTS-5 (aggrecanase-2) was per- 
formed by real-time RT-PCR (ABI PRISM). 
Results: Adenoviral overexpression of active PRSS11 resulted 
in significant reduction of aggrecan content (90-100%) in human 
chondrocyte-alginate cultures, whereas the PRSS11 ASM had 
no such effect. Expression of full-length PRSS11 at a lower level 
(using a different adenoviral vector) also significantly inhibited ag- 
grecan synthesis, but to a lesser extent, and inclusion of CPII/III 
agonist peptide in such cultures further enhanced the inhibitory 
effects of PRSS11. Non-infected human chondrocytes (which ex- 
press endogenous PRSS11) exposed to CPII/III agonist peptide 
displayed reduced expression of aggrecan mRNA, with concomi- 
tant upregulation of mRNAs for ADAMTS-4 and ADAMTS-5. 
Conclusions: Expression of PRSS11 in human chondrocytes 
may lead to a 'catabolic' phenotype, potentially via its docu- 
mented ability to antagonize TGFI~ family proteins. In addition, 
PRSS11 activity may be potentiated through PDZ domain interac- 
tions with agonist peptides uch as CPII/III. Elevated levels of col- 
lagen II C-propeptide in human articular cartilage are observed in 
association with OA as a result of increased collagen synthesis, 
and this may contribute to part of a 'feedback' mechanism to pro- 
mote disease progression. 
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Aims: To investigate whether following cyclical mechanical stim- 
ulation (MS), which up-regulates proteoglycan (PG) synthesis 
as shown in our previous studies, involves selective activation 
of mitogen-activated protein kinases (MAPKs) and to examine 
whether MS is associated with integrin-dependent or indepen- 
dent activation of MAPKs using human chondrocyte cell lines as 
a model. 
Methods: The C-28/12 and C-20/A4 human chondrocyte cell 
lines were mechanically stimulated for 0.5, 1, 2, and 3 hours at 
0.33 Hz, 30,700 i~strain, in monolayer cell culture. PG synthesis 
was assessed by [35S]-sulphate incorporation in the absence or 
presence of the p38 inhibitor SB203580 or the ERK1/2 inhibitor 
PD98059. Kinase expression and activation were assessed by 
Western blotting using phosphorylation status-dependent and 
independent antibodies also in the absence or presence of 
SB203580 and PD98059, and by kinase assays. The JNK in- 
hibitor SP600125 and the function-blocking antibody, CD 29, 
were used to assess JNK activation and integrin dependence re- 
spectively. 
Results: Increased PG synthesis following 3 hours of cyclic MS 
was abolished by pretreatment with 10 I~M SB203580, but was 
not affected by 50 I~M PD98059. The kinases ERK1/ERK2, p38 
and JNK were expressed in both stimulated and un-stimulated 
cells. The phosphorylation of 54 kDa and 48 kDa JNKs increased 
following 05, 1,2 and 3 hours of MS while the 46 kDa JNK protein, 
which was phosphorylated in un-stimulated cells, was dephos- 
phorylated after 1 and 2 hours MS, returning to the basal levels 
following 3 hours of MS. Phosphorylated p38 was not detected 
and phosphorylated ERK1 and ERK2 were unaffected by MS. 
JNK phosphorylation induced by MS was blocked by SB203580 
at 10 I~M or greater and activation of JNK following MS was 
blocked by the SP600125 inhibitor (_>101~M) and partially inhib- 
ited by the anti-I~l integrin blocking antibody. 
Conclusions: These data demonstrate that selective activation 
of JNK following clyclical MS in human chondrocyte cell lines is 
partially integrin dependent and suggest a mechanism for the in- 
creases in proteoglycan synthesis reported previously. 
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Aim of Study: Glucosamine sulfate (GS) was reported to inhibit 
IL-11~-induced expression of genes involved in inflammation and 
cartilage matrix degradation. The purpose of the present study 
was to investigate in a validated chondrocyte model whether GS 
also modulates the cytokine-stimulated expression of early re- 
sponse genes, including NFkB (Rel A, Rel B, NFkB1, NFkB2)and 
AP-1 (June B) family members, as well as EGR-1 that is also an 
upstream regulator of cell proliferation, differentation and apopto- 
sis. 
Methods: Confluent human chondrosarcoma cells SW1353 were 
pretreated for 1 hour with GS 10 I~M, i.e. close to the average 
peak glucosamine concentration found in plasma after oral ad- 
ministration of the full once-daily therapeutic dose, or with 0.1 I~M, 
i.e. a 100-fold lower concentration. Cultures were then stimulated 
with IL-11~ either 2 or 10 ng/ml. RealTime PCR analysis was used 
to quantify gene expression levels after appropriate time expo- 
sure to the stimulus (i.e. 1 hour for JunB/EGR-1 and 2 hours for 
NF-kB family members). All experiments were performed three 
times. 
Results: I1-11~ markedly increased the expression of the above 
mentioned genes, RelA being induced to a lesser extent. Pre- 
treatment with GS consistently induced a marked reduction in the 
